:::
INER MIBI KIT, a diagnosis agent to detect early-staged heart disease and breast cancer, was approved for local marketing in February, 2008, and excellent results have been obtained in the last eight month. The price of INER MIBI KIT is between one half and one third of the imports. In the future, the use of INER MIBI KIT with Molecular Breast Imaging (MBI), the newest related technology reported in USA last July, can overcome the limitation of current mammography that is not effective to diagnose breast tumors with diameters less than two centimeters and is not useful for dense breasts of oriental women. While the sensitivity of both MBI and Magnetic Resonance Imaging (MRI) are over 90%, the cost for MBI is much less than that for MRI by four-to-six times. Therefore, MBI has the potential to become a widely used diagnostic modality.
According to the statistics published in 2007 by the Department of Health (DOH), cancer and heart diseases are the first and second leading cause of mortality in Taiwan,. Coronary artery disease is ranked as the third prevalent cardiovascular disease, the most common cause of sudden death. In addition, breast cancer is the most prevalent female cancer in Taiwan. If breast cancer and heart disease can be early diagnosed and treated in high-risk populations, the mortality, medical cost, and social resources associated with the diseases will be remarkably reduced. For example, the survival rates of patients with stage zero and stage two breast cancer are about 98 100% and 65%, respectively. Technetium-99m-MIBI has been widely used to diagnose heart disease and breast cancer in developed countries for many years, because of its many advantages in clinical application. However, as MIBI is patented by the pharmaceutical company, the price of imported technetium-99m-MIBI is so high that its use has been limited in Taiwan. Consequently, it is extremely expensive to receive a better medical care for Taiwanese patients who need technetium-99m-MIBI for diagnosis.
With the approval of INER MIBI KIT for diagnosis of heart disease and breast cancer, it is estimated that about eighty thousand patients can benefit from the use of MIBI every year and the annual market is about 240 million NTD in Taiwan. INER MIBI KIT can be used together with the portable breast imaging system which is under development by INER to fulfill the need for breast imaging examination in local clinics in Taiwan. In addition, INER is currently developing therapeutic radiopharmaceuticals for the treatment of breast cancer, such as Rhenium-188/Lutetium-177 -Herceptin. The successful marketing of INER MIBI KIT will provide good health care to those who need it, and the cost of MIBI is also markedly reduced.
INER MIBI KIT, a diagnosis agent to detect early-staged heart disease and breast cancer, has been successfully approved for local marketing--(20081110)
Last Update: Jun 23, 2020
INER MIBI KIT, a diagnosis agent to detect early-staged heart disease and breast cancer, was approved for local marketing in February, 2008, and excellent results have been obtained in the last eight month. The price of INER MIBI KIT is between one half and one third of the imports. In the future, the use of INER MIBI KIT with Molecular Breast Imaging (MBI), the newest related technology reported in USA last July, can overcome the limitation of current mammography that is not effective to diagnose breast tumors with diameters less than two centimeters and is not useful for dense breasts of oriental women. While the sensitivity of both MBI and Magnetic Resonance Imaging (MRI) are over 90%, the cost for MBI is much less than that for MRI by four-to-six times. Therefore, MBI has the potential to become a widely used diagnostic modality.
According to the statistics published in 2007 by the Department of Health (DOH), cancer and heart diseases are the first and second leading cause of mortality in Taiwan,. Coronary artery disease is ranked as the third prevalent cardiovascular disease, the most common cause of sudden death. In addition, breast cancer is the most prevalent female cancer in Taiwan. If breast cancer and heart disease can be early diagnosed and treated in high-risk populations, the mortality, medical cost, and social resources associated with the diseases will be remarkably reduced. For example, the survival rates of patients with stage zero and stage two breast cancer are about 98 100% and 65%, respectively. Technetium-99m-MIBI has been widely used to diagnose heart disease and breast cancer in developed countries for many years, because of its many advantages in clinical application. However, as MIBI is patented by the pharmaceutical company, the price of imported technetium-99m-MIBI is so high that its use has been limited in Taiwan. Consequently, it is extremely expensive to receive a better medical care for Taiwanese patients who need technetium-99m-MIBI for diagnosis.
With the approval of INER MIBI KIT for diagnosis of heart disease and breast cancer, it is estimated that about eighty thousand patients can benefit from the use of MIBI every year and the annual market is about 240 million NTD in Taiwan. INER MIBI KIT can be used together with the portable breast imaging system which is under development by INER to fulfill the need for breast imaging examination in local clinics in Taiwan. In addition, INER is currently developing therapeutic radiopharmaceuticals for the treatment of breast cancer, such as Rhenium-188/Lutetium-177 -Herceptin. The successful marketing of INER MIBI KIT will provide good health care to those who need it, and the cost of MIBI is also markedly reduced.
